|Day Low/High||299.71 / 304.68|
|52 Wk Low/High||215.78 / 374.99|
After Friday's surge another look at BIIB is warranted.
The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending market topics from the floor of the New York Stock Exchange.
Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
At midday tech, biotech ( dragging the group higher), homebuilders and energy are leading to the upside. There are really no large underperformers - though on a relative sense, autos, cap goods and semis are trailing. Banks fell initially, on the "d...
There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.
This biotech's weekly chart is very encouraging.
First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.
My longer-term price target is now $416.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.
I think M&A activity will pick up markedly going forward across the industry.
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
Charts are signalling more trouble ahead for the stock.
The biotech sector has seen a big rally, but there are still opportunities.
The challenge of this market is to keep finding new buy entries as more and more stocks become extended.
Consumer spending should be more than solid given wage increases.
About a half hour to go before the markets open for the last trading day of the week. Acorda Therapeutics is up more than 10% in pre-market trading on rumors it could be the target of several potential suitors, including Biogen . Juno Therapeutics h...
Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.
These favorite names in the volatile sector offer the potential for high rewards.
Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.
Stocks closed confidently higher Tuesday.
Strong earnings from Dow components Caterpillar, McDonald's and 3M were on track to push the blue-chip index higher after a 0.23% decline on Monday.